CN106581663A - Composition for treating hormone-dependent dermatitis - Google Patents
Composition for treating hormone-dependent dermatitis Download PDFInfo
- Publication number
- CN106581663A CN106581663A CN201611262087.5A CN201611262087A CN106581663A CN 106581663 A CN106581663 A CN 106581663A CN 201611262087 A CN201611262087 A CN 201611262087A CN 106581663 A CN106581663 A CN 106581663A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- composition
- soft tissue
- dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 34
- 230000001419 dependent effect Effects 0.000 title claims abstract description 25
- 239000005556 hormone Substances 0.000 title claims abstract description 8
- 229940088597 hormone Drugs 0.000 title claims abstract description 8
- 241000237536 Mytilus edulis Species 0.000 claims abstract description 57
- 235000020638 mussel Nutrition 0.000 claims abstract description 55
- 210000004872 soft tissue Anatomy 0.000 claims abstract description 46
- 229940064064 purslane extract Drugs 0.000 claims abstract description 33
- 150000003431 steroids Chemical class 0.000 claims description 22
- 230000001815 facial effect Effects 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 235000001855 Portulaca oleracea Nutrition 0.000 claims description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 229940094952 green tea extract Drugs 0.000 claims description 6
- 235000020688 green tea extract Nutrition 0.000 claims description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 241000219304 Portulacaceae Species 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- -1 flavouring Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 241001245601 Perna viridis Species 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 235000014103 egg white Nutrition 0.000 claims description 2
- 210000000969 egg white Anatomy 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000015170 shellfish Nutrition 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000003070 absorption delaying agent Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 31
- 241001071917 Lithospermum Species 0.000 abstract description 5
- 239000003862 glucocorticoid Substances 0.000 abstract description 5
- 102000004142 Trypsin Human genes 0.000 abstract description 3
- 108090000631 Trypsin Proteins 0.000 abstract description 3
- 230000003266 anti-allergic effect Effects 0.000 abstract description 3
- 201000004681 Psoriasis Diseases 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 210000004927 skin cell Anatomy 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000012588 trypsin Substances 0.000 abstract description 2
- 208000020154 Acnes Diseases 0.000 abstract 1
- 206010005913 Body tinea Diseases 0.000 abstract 1
- 241000905957 Channa melasoma Species 0.000 abstract 1
- 206010012432 Dermatitis acneiform Diseases 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000002474 Tinea Diseases 0.000 abstract 1
- 206010067197 Tinea manuum Diseases 0.000 abstract 1
- 201000010916 acneiform dermatitis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 201000003875 tinea corporis Diseases 0.000 abstract 1
- 201000004647 tinea pedis Diseases 0.000 abstract 1
- 231100001274 therapeutic index Toxicity 0.000 description 30
- 208000024891 symptom Diseases 0.000 description 21
- 238000011084 recovery Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 240000001592 Amaranthus caudatus Species 0.000 description 6
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 6
- 239000004178 amaranth Substances 0.000 description 6
- 235000012735 amaranth Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 206010033733 Papule Diseases 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 206010043189 Telangiectasia Diseases 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 230000000116 mitigating effect Effects 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000009056 telangiectasis Diseases 0.000 description 5
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 4
- 229930003537 Vitamin B3 Natural products 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 235000019160 vitamin B3 Nutrition 0.000 description 4
- 239000011708 vitamin B3 Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 235000004256 Buglossoides arvense Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000118841 Lithospermum incisum Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000004229 Alkannin Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001147138 Mytilus galloprovincialis Species 0.000 description 2
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 235000019232 alkannin Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- 208000000993 Dendritic Keratitis Diseases 0.000 description 1
- 241000555268 Dendroides Species 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000234609 Portulaca oleracea Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 108010027252 Trypsinogen Proteins 0.000 description 1
- 102000018690 Trypsinogen Human genes 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 125000000627 niacin group Chemical group 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a composition for treating hormone-dependent dermatitis. The composition comprises mussel soft tissue extract, trypsin, Lithospermum erythrorhizon extract and purslane extract, and also optionally comprises other carriers. The composition has anti-inflammation, anti-allergy, restoration and flesh engendering effects, and has a good treatment effect on the hormone-dependent dermatitis through adjusting the immunity of skins and promoting metabolism of skin cells, the above formula contains no glucocorticoid substances or antibiotics and can be used for a long term without generating dependence, and the composition is also suitable for acnes, acneiform dermatitis, various eczemas, acute and chronic dermatitis, mite dermatitis, and fungus induced psoriasis, porrigo, tinea corporis and manus and tinea pedis, has no toxic or side effects, and has high safety and large cure rate when clinically used.
Description
Technical field
The present invention relates to biomedicine technical field, more particularly, to a kind of combination for treating steroid dependent dermatitis
Thing.
Background technology
Steroid dependent dermatitis is the dermatitis caused because of prolonged and repeated improperly external application hormone, shows as external application sugar cortical hormone
Primary skin damaged disappears after element, but inflammatory damage occurs again after disabling, and needs Reusability glucocorticoid to control symptom and gradually
A kind of dermatitis for increasing.
Steroid dependent dermatitis has the two big origin causes of formation：First is that chronic skin patient abuses for a long time medicine formation
Steroid dependent dermatitis, patient pursues the reasons such as drug effect is rapid when facial skin disease is treated, and causes facial sugar cortex
The generation of steroid dependent dermatitis is in rising trend, and this is that more traditional disease sends out reason；Second is Zhong Duoai in recent years
Beauty scholar has been used with cosmetics the effects such as nti-freckle, whitening, crease-resistant, tender skin, anti-acne, antiallergic, many illegal businessmans in order to
Product quick acting is pursued, glucocorticoid is added into cosmetics and aesthetic care products, particularly internet is quick
Development, to more three-without-products containing glucocorticoid huge living space is provided, and accelerates steroid dependent dermatitis
The flood tide outburst of patient populations.
Mussel (Mytilusedulis Linnaeus) is a kind of sea mollusk, belongs to bivalve shellfish, is commonly called as " blue or green
Mouthful " and " mussel ", each coastwise contries of throughout world.Mussel species are various, and only coastal area of china just has kind more than 30, and economic worth is higher
Have kind more than 10, wherein Mytilus galloprovincialis, Perna viridis and Trachyostracous mussel is main breed variety.Enriched Mussel containing protein, fat,
The nutrients such as carbohydrate, calcium, phosphorus, iron, riboflavin, niacin, and with very high medical value.
Trypsase (Trypsin, Parenzyme), EC 3.4.21.4 are the one kind extracted from the pancreas of ox, sheep, pig
Serine protein hydrolase.The precursor trypsinogen of pancreas manufacture is secreted into after small intestine, and erepsin activates it, becomes pancreas egg
White enzyme.Trypsase is endopeptidase, the carboxyl that it can optionally in the lysine and arginine residues of hydrolyzed peptide chain.
Trypsase not only plays digestive ferment, and can also limit decomposition chymotrypsinogen, procarboxypeptidase, phosphatide proenzyme etc. other
The precursor of enzyme, plays activation.
Asian puccoon (Lithospermum erythrorhizon Sieb.et Zucc) is Boraginaceae Lithospermum perennial herb
Plant, Radix Arnebiae extract is a kind of chemical substance, also known as shikonin, shikonin, d-alkanin, purple flaky crystal or crystallinity powder
End, 147～149 DEG C of fusing point ,+138 ° of optical activity (benzene) is water insoluble, is dissolved in ethanol, organic solvent and vegetable oil.It is soluble in alkali
Water, meets acid Precipitation again.Alkannin, with the effect such as anticancer, anti-inflammatory, antibacterial, is clinically used for treating acute hepatitis, chronic hepatitis, liver
Hardening (ascites)；Dept. of dermatology is used to treat flat wart, psoriasis, topical application treatment burn and promotion wound healing；Eye drops
For treating herpes simplex keratitis, there is certain curative effect to epitheliated type dendroid and shallow essential layer dendritic keratitis；Finish
For treating infant dermatitis, eczema, vaginitis, cervicitis etc.；Toothpaste containing alkannin can prevent and treat tooth dental caries and gingivitis；Also
Can be used for the colouring agent of medicine, cosmetics and food.
Purslane (Portulacaoleracea L), is portulacaceous plant, is the traditional Chinese medicine of China, with scattered blood
Detumescence, it is clearing heat and detoxicating the effect of, be one of 78 kinds of integration of drinking and medicinal herbs wild plants of the Ministry of Public Health of China regulation.The herb of purslane
Containing materials such as abundant adrenaline, flavones, cardiac glycosides, result of study shows：Contain what is enriched in seed, the leaf of purslane
Omega-fatty acid, omega-fatty acid can effectively reduce arachidonic generation, unsaturated in human body (especially skin)
Aliphatic acid is important anti-inflammatory component.Purslane extract is to extract to be had from the stem and leaf of purslane using low temperature method
There is the extract of biologically active, and be dissolved in certain density butanediol solution, with anti-drying aging, increase skin in the winter time
Skin comfort level and removing free radical, improve the combination property of skin comfort etc..
Steroid dependent dermatitis is a kind of refractory dermatoses, and current clinical treatment steroid dependent dermatitis is relied primarily on
Hormone decreasing therapy, immunosuppressant treatment method, Treatment of TCM, also need to combination antibiotic treatment when serious.Even if such as
This, nor especially desirable, treatment cycle is long, large side effects for traditional therapeutic effect, and knock-on is frequent, and overall cure rate is low,
Make troubles to patient work, life.
The content of the invention
For solve the treatment existing for existing steroid dependent dermatitis treatment product not thoroughly, easily repeatedly, side effect it is strong, easily
The defect such as the resistance to the action of a drug or DeGrain is formed, the present invention proposes a kind of composition for treating steroid dependent dermatitis, including
Mussel soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract.
One or more embodiments of the invention, the composition can be by weight：Mussel soft tissue is carried
Take thing 0.2-20 parts, trypsase 0.2-10 parts, Radix Arnebiae extract 1-10 parts and purslane extract 5-10 parts.
One or more embodiments of the invention, based on the weight of composition, mussel soft tissue extract can be with
Such as 0.2 part, 0.25 part, 0.3 part, 0.35 part, 0.4 part, 0.45 part, 0.5 part, 0.55 part, 0.6 part, 0.65 part, 0.7 part,
0.75 part, 0.8 part, 0.85 part, 0.9 part, 0.95 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts,
5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts,
12.5 parts, 13 parts, 13.5 parts, 14 parts, 14.5 parts, 15 parts, 15.5 parts, 16 parts, 16.5 parts, 17 parts, 17.5 parts, 18 parts, 18.5
Part, 19 parts, 19.5 parts, 20 parts etc., trypsase can be such as 0.2 part, 0.25 part, 0.3 part, 0.35 part, 0.4 part, 0.45
Part, 0.5 part, 0.55 part, 0.6 part, 0.65 part, 0.7 part, 0.75 part, 0.8 part, 0.85 part, 0.9 part, 0.95 part, 1 part, 1.5
Part, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts,
9.5 parts, 10 parts etc., Radix Arnebiae extract can be such as 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts,
5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts etc., purslane extract can be such as 5
Part, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, any concrete weight portion in 10 parts etc..
Further, the composition also includes by weight：Vitamin B3：10～40 parts, vitamin B2：1～10 part,
Vitamin E：10～20 parts, L- vitamin Cs：5～20 parts, green-tea extract 5-10 parts.
One or more embodiments of the invention, in the composition：Mussel soft tissue extract, tryptose
Enzyme, Radix Arnebiae extract and purslane extract can be individually insulated presence or can be mixed.Here, " isolation is present " refers to
Four kinds of compositions exist with the non-interfering independent packaging for keeping respective property." being mixed " refers to that four kinds of compositions are mixed
In a packaging, then or, the combination of two component/tri- components is present, and separates with other components and exist.
One or more embodiments of the invention, in the composition：Mussel soft tissue extract and tryptose
Enzyme, Radix Arnebiae extract and purslane extract can be dry powder.
One or more embodiments of the invention, in the composition：Mussel soft tissue extract and tryptose
Enzyme, Radix Arnebiae extract and purslane extract can be liquid.
One or more embodiments of the invention, the composition is formulated as the final ph after liquid for 2.5-
9.0, for example, it is preferable to pH value is 4.5-8.0, or, such as preferable ph is 5.5-7.0.
One or more embodiments of the invention, the mussel soft tissue extract refer to mussel except shell with
Outer component namely mussel soft tissue is raw material, is extracted and the supernatant of acquisition, wherein protein content through acidic aqueous solution
For 0.2-15mg/ml, pH value 1.0-6.0.Especially, can be with byssus as raw material.
One or more aspects of the invention, the mussel includes in Mytilus galloprovincialis, Perna viridis, Trachyostracous mussel
Kind, two or three.
One or more embodiments of the invention, the acidic aqueous solution can include：Acetic acid-acetate buffer
Liquid, acetic acid, citric acid, perchloric acid etc., but not limited to this.
One or more embodiments of the invention, the protein content of the mussel soft tissue extract can be
Such as 0.2mg/ml, 0.3mg/ml, 0.4mg/ml, 0.5mg/ml, 0.6mg/ml, 0.7mg/ml, 0.8mg/ml, 0.9mg/ml,
1.0mg/ml、1.5mg/ml、2.0mg/ml、2.5mg/ml、3.0mg/ml、3.5mg/ml、4.0mg/ml、4.5mg/ml、
5.0mg/ml、5.5mg/ml、6.0mg/ml、6.5mg/ml、7.0mg/ml、7.5mg/ml、8.0mg/ml、8.5mg/ml、
9.0mg/ml、9.5mg/ml、10.0mg/ml、10.5mg/ml、11.0mg/ml、11.5mg/ml、12.0mg/ml、12.5mg/
Ml, 13.0mg/ml, 13.5mg/ml, 14.0mg/ml, 14.5mg/ml and 15.0mg/ml etc., but not limited to this.
One or more embodiments of the invention, the trypsase can be conventional purchase from the market.
Alternatively, the trypsase can be by saltouing, it is prepared by the method such as column chromatography.
One or more embodiments of the invention, the Radix Arnebiae extract can be conventional purchase from the market
's.Alternatively, the Radix Arnebiae extract can be by method systems such as direct extraction method, soxhlet extraction, ultrasonic extractions
Standby.
One or more embodiments of the invention, the purslane extract can be conventional purchase from the market
's.Alternatively, the purslane extract can be prepared by methods such as water extraction method, enzyme extraction method, ultrasonic extractions
's.
Another aspect of the present invention is related to a kind of pharmaceutical composition for treating steroid dependent dermatitis, wherein, the medicine
Composition can include mussel soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract.
One or more embodiment of the invention, described pharmaceutical composition can also include pharmaceutically acceptable
Carrier.
One or more embodiments of the invention, described pharmaceutical composition can be foaming agent.
One or more embodiments of the invention, described pharmaceutical composition can be gel.
One or more embodiments of the invention, described pharmaceutical composition can be effervescent tablet.
One or more embodiments of the invention, described pharmaceutical composition can be emulsion.
One or more embodiments of the invention, the carrier can include any and all of solvent, salt,
Decentralized medium, coating material, surfactant, antioxidant, preservative (such as antiseptic, antifungal agent), isotonic agent, absorption
Delayed-action activator, drug stabilizing agent, adhesive, excipient, disintegrant, lubricant, sweetener, flavouring, dyestuff etc. and they in one
Kind, various or whole combinations, this is well-known to those skilled in the art (for example, see Remington's
Pharmaceutical Sciences,18th Ed.Mack Printing Company,1990,pp.1289-1329).Except
Outside the carrier incompatible with active component, it is contemplated that any conventional carrier used in treatment use or pharmaceutical composition.
One or more embodiments of the invention, to experimenter in need combination of the invention is given
Thing, the composition is made up of mussel soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract.
One or more embodiments of the invention, the mussel soft tissue extract, trypsase, Asian puccoon are extracted
Thing and purslane extract can be mixed in composition.
One or more embodiments of the invention, the mussel soft tissue extract, trypsase, Asian puccoon are extracted
Thing and purslane extract can be individually insulated to be present in composition.Here, when by mussel soft tissue extract, tryptose
When enzyme, Radix Arnebiae extract and purslane extract combination medicine-feeding, administration can be order of administration or be administered simultaneously, preferably can be with
It is order of administration.For order of administration, can be by mussel soft tissue extract, trypsase, Radix Arnebiae extract and dent
Amaranth extract is administered in any order.For example, can first give mussel soft tissue extract and give trypsase again and give purple again
Careless extract and purslane extract, with this sequence alternate administration whole treatment is continued, or can first give trypsase again
Give mussel soft tissue extract and give Radix Arnebiae extract and purslane extract again, continue entirely to control with this sequence alternate administration
Treat, or can be in every day for the treatment of with different order administration.
The beneficial effect of the invention is：Said composition has anti-inflammatory, antiallergic, reparation, promoting muscle growth functions, by adjusting skin
Immunologic function and promotion skin cell metabolism, for treatment cosmetics contact dermatitis, steroid dependent dermatitis have
Good effect, in the formula of the present invention glucocorticoids material and antibiotic are not contained, and Long-Time Service does not have dependence, nothing
Toxic and side effect, Clinical practice is safe and cure rate ratio is big.
Specific embodiment
Following examples are illustrated by taking the composition for treating steroid dependent dermatitis as an example, but not limited to this, above-mentioned
Invention propose the various hormones comprising mussel soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract according to
Bad property dermatitis in treatment product is applied to the present invention.
Embodiment 1：The preparation method of mussel soft tissue extract.
Take mussel to shell, collect soft tissue 300g, be divided into three parts, per part adds in the table 1 below of 100ml contents 0.3%
Acid solution, centrifugation after homogenate 10min obtains supernatant and is mussel soft tissue extract.
Protein content and pH value in supernatant is determined, protein content is determined using Coomassie Brilliant Blue.
Table 1
| Example | Acid solution | Protein content | PH value |
| 1 | Citric acid | 2.6mg/ml | 4.5 |
| 2 | Acetic acid | 3.5mg/ml | 3.2 |
| 3 | Perchloric acid | 3.0mg/ml | 1.0 |
Embodiment 2：A kind of combination of mussel soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract
Object plane film.
Composition in the present embodiment is combined by following weight：Mussel soft tissue extract 10mg, trypsase
10mg, Radix Arnebiae extract 15mg and purslane extract 15mg, vitamin B3：5mg, vitamin B2：3mg, vitamin E：
15mg, L- vitamin C：16mg, green-tea extract 15mg, add deionized water to form facial mask liquid after fully dissolving.By face paper
Face is spread on after absorbent solution in immersion facial mask liquid, 15-20 removes facial mask after minute.
Collect 12 volunteers and participate in test, using mussel soft tissue extract, trypsase, Radix Arnebiae extract and dent
The composition facial mask of amaranth extract, applies once daily, and 10 days is a course for the treatment of, and recurrence is paid a return visit and recorded in 1 month.
Curative effect determinate standard：Parameters for observation on effect includes skin damaged (erythema, papule, acne infringement, telangiectasis)
And itch.
Standards of grading：Indices are scored by 4 grades of point systems：0 point=nothing, 1 point=slight, 2 points=moderate, 3
Point=severe.Evaluated according to therapeutic index, integrate before therapeutic index=(integrating after integrating before treatment-treating)/treatment ×
100%.
Recovery from illness：Skin damaged and symptom disappear, therapeutic index ＞ 90%；
It is effective：Skin damaged is most of to disappear, and symptom substantially mitigates, and therapeutic index is 60%～90%；
Take a turn for the better：Skin damaged and symptom mitigation, therapeutic index is 20%～59%；
It is invalid：Skin damaged and symptom are not improved, therapeutic index ＜ 20%.
Total effective rate fully recovering+it is effective in terms of.
Curative effect is shown in Table 2.
Table 2:Test curative effect
| Recovery from illness | It is effective | Take a turn for the better | It is invalid | It is total | Efficient (%) |
| 6 | 5 | 1 | 0 | 12 | 91.67 |
Embodiment 3：A kind of combination of mussel soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract
Object plane film.
Composition in the present embodiment is combined by following weight：Mussel soft tissue extract 50mg, trypsase
30mg, Radix Arnebiae extract 25mg and purslane extract 25mg, vitamin B3：60mg, vitamin B2：15mg, vitamin E：
30mg, L- vitamin C：30mg, green-tea extract 25mg, add deionized water to form facial mask liquid after fully dissolving.By face paper
Face is spread on after absorbent solution in immersion facial mask liquid, 15-20 removes facial mask after minute.
Collect 14 volunteers and participate in test, using mussel soft tissue extract, trypsase, Radix Arnebiae extract and dent
The composition facial mask of amaranth extract, applies once daily, and 10 days is a course for the treatment of, and recurrence is paid a return visit and recorded in 1 month.
Curative effect determinate standard：Parameters for observation on effect includes skin damaged (erythema, papule, acne infringement, telangiectasis)
And itch.
Standards of grading：Indices are scored by 4 grades of point systems：0 point=nothing, 1 point=slight, 2 points=moderate, 3
Point=severe.Evaluated according to therapeutic index, integrate before therapeutic index=(integrating after integrating before treatment-treating)/treatment ×
100%.
Recovery from illness：Skin damaged and symptom disappear, therapeutic index ＞ 90%；
It is effective：Skin damaged is most of to disappear, and symptom substantially mitigates, and therapeutic index is 60%～90%；
Take a turn for the better：Skin damaged and symptom mitigation, therapeutic index is 20%～59%；
It is invalid：Skin damaged and symptom are not improved, therapeutic index ＜ 20%.
Total effective rate fully recovering+it is effective in terms of.
Curative effect is shown in Table 3.
Table 3:Test curative effect
| Recovery from illness | It is effective | Take a turn for the better | It is invalid | It is total | Efficient (%) |
| 5 | 8 | 1 | 0 | 14 | 92.85 |
Embodiment 4：A kind of combination of mussel soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract
Object plane film.
Composition in the present embodiment is combined by following weight：Mussel soft tissue extract 18mg, trypsase
16mg, Radix Arnebiae extract 18mg and purslane extract 20mg, add deionized water to form facial mask liquid after fully dissolving.By face
Face is spread on after absorbent solution in film paper immersion facial mask liquid, 15-20 removes facial mask after minute.
Collect 18 volunteers and participate in test, using mussel soft tissue extract, trypsase, Radix Arnebiae extract and dent
The composition facial mask of amaranth extract, applies once daily, and 10 days is a course for the treatment of, and recurrence is paid a return visit and recorded in 1 month.
Curative effect determinate standard：Parameters for observation on effect includes skin damaged (erythema, papule, acne infringement, telangiectasis)
And itch.
Standards of grading：Indices are scored by 4 grades of point systems：0 point=nothing, 1 point=slight, 2 points=moderate, 3
Point=severe.Evaluated according to therapeutic index, integrate before therapeutic index=(integrating after integrating before treatment-treating)/treatment ×
100%.
Recovery from illness：Skin damaged and symptom disappear, therapeutic index ＞ 90%；
It is effective：Skin damaged is most of to disappear, and symptom substantially mitigates, and therapeutic index is 60%～90%；
Take a turn for the better：Skin damaged and symptom mitigation, therapeutic index is 20%～59%；
It is invalid：Skin damaged and symptom are not improved, therapeutic index ＜ 20%.
Total effective rate fully recovering+it is effective in terms of.
Curative effect is shown in Table 4.
Table 4:Test curative effect
| Recovery from illness | It is effective | Take a turn for the better | It is invalid | It is total | Efficient (%) |
| 6 | 10 | 2 | 0 | 18 | 88.89 |
Embodiment 5：A kind of combination of mussel soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract
Object plane film.
Composition in the present embodiment is combined by following weight：Mussel soft tissue extract 12mg, trypsase
13mg, Radix Arnebiae extract 20mg and purslane extract 18mg, vitamin B3：25mg, vitamin B2：8mg, vitamin E：
25mg, L- vitamin C：26mg, green-tea extract 18mg, add deionized water to form facial mask liquid after fully dissolving.By face paper
Face is spread on after absorbent solution in immersion facial mask liquid, 15-20 removes facial mask after minute.
Collect 10 volunteers and participate in test, using mussel soft tissue extract, trypsase, Radix Arnebiae extract and dent
The composition facial mask of amaranth extract, applies once daily, and 10 days is a course for the treatment of, and recurrence is paid a return visit and recorded in 1 month.
Curative effect determinate standard：Parameters for observation on effect includes skin damaged (erythema, papule, acne infringement, telangiectasis)
And itch.
Standards of grading：Indices are scored by 4 grades of point systems：0 point=nothing, 1 point=slight, 2 points=moderate, 3
Point=severe.Evaluated according to therapeutic index, integrate before therapeutic index=(integrating after integrating before treatment-treating)/treatment ×
100%.
Recovery from illness：Skin damaged and symptom disappear, therapeutic index ＞ 90%；
It is effective：Skin damaged is most of to disappear, and symptom substantially mitigates, and therapeutic index is 60%～90%；
Take a turn for the better：Skin damaged and symptom mitigation, therapeutic index is 20%～59%；
It is invalid：Skin damaged and symptom are not improved, therapeutic index ＜ 20%.
Total effective rate fully recovering+it is effective in terms of.
Curative effect is shown in Table 5.
Table 5:Test curative effect
| Recovery from illness | It is effective | Take a turn for the better | It is invalid | It is total | Efficient (%) |
| 4 | 5 | 1 | 0 | 10 | 90.00 |
Embodiment 6：A kind of combination of mussel soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract
Thing.
Composition in the present embodiment is combined by following weight：Mussel soft tissue extract 25mg, trypsase
20mg, Radix Arnebiae extract 12mg and purslane extract 10mg, vitamin B3：18mg, vitamin B2：10mg, vitamin E：
7mg, L- vitamin C：12mg, green-tea extract 18mg, add appropriate emulsifying agent and deionized water to form emulsion after fully dissolving.
Collect 18 volunteers and participate in test, using mussel soft tissue extract, trypsase, Radix Arnebiae extract and dent
The composition of amaranth extract, uses 2 times after daily face cleaning, is massaged into absorption.10 days is a course for the treatment of, pays a return visit and remembers in 1 month
Record recurrence.
Curative effect determinate standard：Parameters for observation on effect includes skin damaged (erythema, papule, acne infringement, telangiectasis)
And itch.
Standards of grading：Indices are scored by 4 grades of point systems：0 point=nothing, 1 point=slight, 2 points=moderate, 3
Point=severe.Evaluated according to therapeutic index, integrate before therapeutic index=(integrating after integrating before treatment-treating)/treatment ×
100%.
Recovery from illness：Skin damaged and symptom disappear, therapeutic index ＞ 90%；
It is effective：Skin damaged is most of to disappear, and symptom substantially mitigates, and therapeutic index is 60%～90%；
Take a turn for the better：Skin damaged and symptom mitigation, therapeutic index is 20%～59%；
It is invalid：Skin damaged and symptom are not improved, therapeutic index ＜ 20%.
Total effective rate fully recovering+it is effective in terms of.
Curative effect is shown in Table 6.
Table 6:Test curative effect
| Recovery from illness | It is effective | Take a turn for the better | It is invalid | It is total | Efficient (%) |
| 6 | 10 | 2 | 0 | 18 | 88.89 |
Certainly, the present invention can also have other various embodiments, ripe in the case of without departing substantially from spirit of the invention and its essence
Knowing those skilled in the art can make various corresponding changes and deformation, but these corresponding changes and deformation according to the present invention
The protection domain of the claims in the present invention should all be belonged to.
Claims (10)
1. a kind of composition for treating steroid dependent dermatitis, including mussel soft tissue extract, trypsase, Radix Arnebiae extract
And purslane extract.
2. it is according to claim 1 treatment steroid dependent dermatitis composition, it is characterised in that the composition is by weight
Including：Mussel soft tissue extract 0.2-20 parts, trypsase 0.2-10 parts, Radix Arnebiae extract 1-10 parts and purslane are extracted
Thing 5-10 parts, specifically, based on the weight of composition, mussel soft tissue extract is, for example, 0.2 part, 0.25 part, 0.3 part,
0.35 part, 0.4 part, 0.45 part, 0.5 part, 0.55 part, 0.6 part, 0.65 part, 0.7 part, 0.75 part, 0.8 part, 0.85 part, 0.9
Part, 0.95 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5
Part, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, 12.5 parts, 13 parts, 13.5 parts, 14 parts,
14.5 parts, 15 parts, 15.5 parts, 16 parts, 16.5 parts, 17 parts, 17.5 parts, 18 parts, 18.5 parts, 19 parts, 19.5 parts, 20 parts, pancreas egg
White enzyme is, for example, 0.2 part, 0.25 part, 0.3 part, 0.35 part, 0.4 part, 0.45 part, 0.5 part, 0.55 part, 0.6 part, 0.65 part,
0.7 part, 0.75 part, 0.8 part, 0.85 part, 0.9 part, 0.95 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5
Part, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, Radix Arnebiae extract is, for example, 1
Part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5
Part, 9 parts, 9.5 parts, 10 parts, purslane extract is, for example, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9
Part, 9.5 parts, any concrete weight portion in 10 parts.
3. according to the composition for treating steroid dependent dermatitis of claim 1 or 2, it is characterised in that the composition is also wrapped
Include：Vitamin C, vitamin B2, vitamin E, L- vitamin Cs, green-tea extract.
4. according to the composition for treating steroid dependent dermatitis of aforementioned any claim, wherein in the composition：Mussel
Soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract are individually insulated presence or are mixed；And/or its
Described in protein compositions：Mussel soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract are dry powder
Or liquid.
5. according to the composition for treating steroid dependent dermatitis of aforementioned any claim, wherein the composition is formulated as liquid
Final ph after body is 2.5-9.0, for example, it is preferable to pH value is 4.5-8.0, for example, it is preferable to pH value is 5.5-7.0.
6. according to the composition for treating steroid dependent dermatitis of aforementioned any claim, wherein the mussel soft tissue is extracted
Thing is that, with mussel soft tissue as raw material, the supernatant for extracting through acidic aqueous solution and obtaining, wherein protein content are 0.2-
15mg/ml, pH value 1.0-6.0.
7. according to the composition for treating steroid dependent dermatitis of aforementioned any claim, wherein the mussel is made a gift of including purple
One kind in shellfish, Perna viridis, Trachyostracous mussel, two or three, and/or wherein described acidic aqueous solution includes：Acetic acid-acetic acid
Sodium buffer solution, acetic acid, citric acid, perchloric acid, or the protein content of wherein described mussel soft tissue extract is, for example,
0.2mg/ml、0.3mg/ml、0.4mg/ml、0.5mg/ml、0.6mg/ml、0.7mg/ml、0.8mg/ml、0.9mg/ml、
1.0mg/ml、1.5mg/ml、2.0mg/ml、2.5mg/ml、3.0mg/ml、3.5mg/ml、4.0mg/ml、4.5mg/ml、
5.0mg/ml、5.5mg/ml、6.0mg/ml、6.5mg/ml、7.0mg/ml、7.5mg/ml、8.0mg/ml、8.5mg/ml、
9.0mg/ml、9.5mg/ml、10.0mg/ml、10.5mg/ml、11.0mg/ml、11.5mg/ml、12.0mg/ml、12.5mg/
Ml, 13.0mg/ml, 13.5mg/ml, 14.0mg/ml, 14.5mg/ml and 15.0mg/ml.
8. a kind of pharmaceutical composition, it is characterised in that described pharmaceutical composition is the treatment hormone according to aforementioned any claim
The composition of dependence facial dermatitis, or including the combination of the treatment steroid dependent dermatitis according to aforementioned any claim
Thing, described pharmaceutical composition includes mussel soft tissue extract, trypsase, Radix Arnebiae extract and purslane extract.
9. pharmaceutical composition according to claim 8, the composite medicine further includes pharmaceutically acceptable carrier, example
Such as solvent, salt, decentralized medium, coating material, surfactant, antioxidant, preservative, isotonic agent, absorption delaying agent, medicine
Stabilizer, adhesive, excipient, disintegrant, lubricant, sweetener, flavouring, dyestuff etc. and they in it is a kind of, various or complete
The combination in portion.
10. pharmaceutical composition according to claim 8 or claim 9, it is characterised in that described pharmaceutical composition is facial mask, emulsion, frost
Agent, paste, spray, gel or gel form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611262087.5A CN106581663A (en) | 2016-12-30 | 2016-12-30 | Composition for treating hormone-dependent dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611262087.5A CN106581663A (en) | 2016-12-30 | 2016-12-30 | Composition for treating hormone-dependent dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581663A true CN106581663A (en) | 2017-04-26 |
Family
ID=58581812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611262087.5A Withdrawn CN106581663A (en) | 2016-12-30 | 2016-12-30 | Composition for treating hormone-dependent dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581663A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648156A (en) * | 2017-10-26 | 2018-02-02 | 广州珈源日化用品有限公司 | A kind of essence lotion of releiving containing mussel extract |
-
2016
- 2016-12-30 CN CN201611262087.5A patent/CN106581663A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648156A (en) * | 2017-10-26 | 2018-02-02 | 广州珈源日化用品有限公司 | A kind of essence lotion of releiving containing mussel extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090110674A1 (en) | Health supplement | |
| US20190125815A1 (en) | Topical Pharmaceutical Composition for Treating Multiple Wounds of Skin and the Preparation Methods Thereof | |
| US20130337090A1 (en) | Plant extracts for treating burns and chronic wounds | |
| JP6425106B2 (en) | Method for producing a herbal medicine composition for skin cooling sensation using jaundice extract | |
| KR102071627B1 (en) | Peeling gel composition for removing keratin of skin and manufacturing method thereof | |
| CN105596277A (en) | Cactus face cream for treating acne and preparation method thereof | |
| CN111265650A (en) | Novel traditional Chinese medicine composition and preparation method thereof | |
| CN105213256A (en) | A kind of Shu Min dispels red toner/smoothing toner and preparation method thereof | |
| CN105107014B (en) | A kind of medical bio skin antiallergic dressing and preparation method thereof | |
| CN106581663A (en) | Composition for treating hormone-dependent dermatitis | |
| CN107049911A (en) | A kind of composition for treating red blood silk and its application | |
| CN106690121A (en) | Trepang, hippophae rhamnoides fruit, cordyceps militaris and selenium preparation and preparation technology thereof | |
| KR101860426B1 (en) | Herb medicine composition for cooling skin temperature rise using phellodendri cortex and manufacturing method thereof and using skin improving goods | |
| CN102919853A (en) | Rana japonica oil soft capsule | |
| CN102771794A (en) | Soft capsule made of seabuckthorn oil and vitamins EC | |
| CN109954052A (en) | A kind of composition with antioxidant activity | |
| CN108619486B (en) | Ointment for treating skin diseases and preparation method thereof | |
| CN105031170A (en) | Healthcare foot bath powder and preparing method thereof | |
| CN110859912A (en) | Traditional Chinese medicine composition for prostatitis and preparation method and application thereof | |
| CN104825379A (en) | Whitening peeling night cream capable of reducing melanin deposition and preparation method thereof | |
| CN114767772B (en) | Pharmaceutical composition for treating acne | |
| CN102948663A (en) | Rana japonica oil granules and preparation method thereof | |
| CN109125413A (en) | A kind of Chinese medicinal composition preparation and preparation method thereof with tonifying kidney and strengthening yang effect | |
| CN106581660A (en) | Composition for treating microbial infection | |
| CN106334176A (en) | Chilblain cream capable of relieving swelling, pain and itching and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170426 |